1
|
Salvetti A, Ferrari V, Garofalo R, Gazzaniga P, Guerroni A, Metrucci A, Sessa A, Severi ML, Nati G, Ruggeri M, Rossi A, Cappellari L, Gopala K, Tosatto R, Simone B. Incidence of herpes zoster and postherpetic neuralgia in Italian adults aged ≥50 years: A prospective study. Prev Med Rep 2019; 14:100882. [PMID: 31193254 PMCID: PMC6522697 DOI: 10.1016/j.pmedr.2019.100882] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/23/2018] [Revised: 04/09/2019] [Accepted: 04/22/2019] [Indexed: 11/23/2022] Open
Abstract
Herpes zoster (HZ) mainly affects older adults and immunocompromised individuals and is usually characterized by a unilateral painful skin rash. Its most common complication, postherpetic neuralgia (PHN), may cause chronic debilitating pain lasting for months or years. This study (ClinicalTrials.gov Identifier: NCT01772160) aimed to estimate the HZ incidence and the proportion of HZ patients with PHN in the Italian population aged 50 years or older. From 2013 to 2016, HZ-patients were recruited when presenting with acute HZ at 75 reporting general practitioners in Italy, covering 43,875 persons aged ≥50 years. PHN was defined as ‘worst pain’ rated ≥ 3 on the Zoster Brief Pain Inventory persisting or appearing over 90 days after rash onset. The overall HZ incidence rate per 1000 person-years (PY) was estimated as 6.46 (95% confidence interval [CI]: 5.99–6.95), increasing with age to 9.12/1000 PY (95% CI: 7.50–10.99) in 75–79 year-olds. Among 391 HZ-patients who completed the study, the overall proportion with PHN was 10.23% (95% CI: 7.41–13.67) and the highest proportion was 15.56% (95% CI: 6.49–29.46) for the 75–79 year-olds. Among the 128 patients (32.7%) who reported at least one pre-existing medical condition, 35.9% reported diabetes mellitus and 32.0% reported emotional problems, stress or depression. The study confirms previous findings that HZ and PHN cause an important clinical burden in older Italian adults. It also confirmed the age-related increasing risk of HZ and PHN. HZ has a strong incidence in the Italian population, the 2nd oldest worldwide. The estimated overall HZ incidence rate was 6.46 per 1000 person-years. The most common complication, PHN, was encountered by 10.23% of HZ patients. Strengths of the study are its prospective design and its large sample. Limitation: incidence may be underestimated due to cases missed in primary care.
Collapse
Affiliation(s)
- Andrea Salvetti
- Investigator site, Piazza Ponchielli 1, Toscana, Grosseto, GR 58100, Italy
| | - Vincenzo Ferrari
- Investigator site, Via Terranova 2, Puglia, Parabita, LE 73052, Italy
| | - Remigio Garofalo
- Investigator site, Via B. di Fredi 24, Toscana, Civitella Paganico, GR 58045, Italy
| | - Pietro Gazzaniga
- Investigator site, Via Garibaldi 1, Piemonte, Frugarolo, AL 15065, Italy
| | - Alessandro Guerroni
- Investigator site, Via Vittorio Veneto 44/A, Lombardia, Sesto Calende, VA 21018, Italy
| | - Antonio Metrucci
- Investigator site, Viale della Repubblica snc, Puglia, Cutrofiano, LE 73020, Italy
| | - Aurelio Sessa
- Investigator site, Via Cavour 26, Lombardia, Arcisate, VA, 21051, Italy
| | | | - Giulio Nati
- Investigator site, Via Pietro Tacchini 7, Lazio, Roma, RM 00197, Italy
| | - Mauro Ruggeri
- Investigator site, Central Site, Società Italiana di Medicina Generale (SIMG), Via del Pignoncino 9 SIMG, Toscana, Firenze, FI 50142, Italy
| | - Alessandro Rossi
- Investigator site, Central Site, Società Italiana di Medicina Generale (SIMG), Via del Pignoncino 9 SIMG, Toscana, Firenze, FI 50142, Italy
| | | | - Kusuma Gopala
- GSK, Embassy Links, Cunningham Road, SRT Road, #5, Bangalore 560052, India
| | | | | |
Collapse
|
2
|
Gabutti G, Valente N, Kuhdari P, Lupi S, Stefanati A. Prevention of herpes zoster and its complications: from the clinic to the real-life experience with the vaccine. J Med Microbiol 2016; 65:1363-1369. [PMID: 27902409 DOI: 10.1099/jmm.0.000386] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/18/2022] Open
Abstract
The erpes zoster is an acute viral illness characterized by a vesicular rash of unilateral distribution, which can eventually cause severe complications, such as post-herpetic neuralgia, ophthalmic zoster, stroke or other neurological complications. In Europe, an incidence of between 2.0 and 4.6 cases per 1000 person-years is estimated, with an increase after 50 years of age. Currently, the therapeutic options for are only partially effective in limiting the acute phase, while the management of complications is frequently complex and not satisfactory. The overall burden of the disease and the elevated costs associated with diagnosis and clinical and therapeutic management led to the development of a new preventive approach through a live attenuated virus vaccine. The vaccine now available decreases the incidence of the disease, post-herpetic neuralgia and the burden of illness. Moreover, the vaccine is safe and well tolerated and it seems to confer long-term protection. Based on the clinical results and evidence provided by the Health Technology Assessment, several countries introduced immunization although with different recommendations and methods of funding.
Collapse
Affiliation(s)
- Giovanni Gabutti
- Medical Sciences Department, University of Ferrara, via Fossato di Mortara 64B, 44121 Ferrara, Italy
| | - Nicoletta Valente
- Medical Sciences Department, University of Ferrara, via Fossato di Mortara 64B, 44121 Ferrara, Italy
| | - Parvanè Kuhdari
- Medical Sciences Department, University of Ferrara, via Fossato di Mortara 64B, 44121 Ferrara, Italy
| | - Silvia Lupi
- Medical Sciences Department, University of Ferrara, via Fossato di Mortara 64B, 44121 Ferrara, Italy
| | - Armando Stefanati
- Medical Sciences Department, University of Ferrara, via Fossato di Mortara 64B, 44121 Ferrara, Italy
| |
Collapse
|
3
|
Abstract
PURPOSE OF REVIEW The purpose of this review is to provide an update on the diagnosis, treatment, and prevention of neuropathic pain. RECENT FINDINGS Neuropathic pain can be debilitating, leading to poor quality of life and functional status. Neuropathic pain results from numerous mechanisms of nerve injury including infectious diseases, complication of medical diseases, and mechanical damage. As a result of the lack of class I evidence for the treatment of numerous neuropathic pain conditions, those diseases without such evidence are often managed, as though neuropathic pain is a singular condition. In diseases such as diabetes, HIV, and herpes infections, the resultant neuropathic pain is often modifiable with prevention strategies. In one of the more prevalent neuropathic pain conditions, radiculopathy, the commonly used treatments lack sufficient evidence to explain their widespread use. SUMMARY The literature reveals that neuropathic pain is underdiagnosed and often undertreated or treated with ineffective or untested modalities. Evolving definitions of neuropathic pain has broadened the range of therapeutic approaches and brought current treatment paradigms under increased scrutiny. The lack of a mechanism-based approach to treatment may be responsible for the lackluster responses seen in most neuropathic pain conditions.
Collapse
|
4
|
Panatto D, Bragazzi NL, Rizzitelli E, Bonanni P, Boccalini S, Icardi G, Gasparini R, Amicizia D. Evaluation of the economic burden of Herpes Zoster (HZ) infection. Hum Vaccin Immunother 2015; 11:245-62. [PMID: 25483704 DOI: 10.4161/hv.36160] [Citation(s) in RCA: 32] [Impact Index Per Article: 3.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/20/2022] Open
Abstract
The main objective of this systematic review was to evaluate the economic burden of Herpes Zoster (HZ) infection. The review was conducted in accordance with the standards of the "Preferred Reporting Items for Systematic Reviews and Meta-Analyses" guidelines. The following databases were accessed: ISI/Web of Knowledge (WoS), MEDLINE/PubMed, Scopus, ProQuest, the Cochrane Library and EconLit. Specific literature on health economics was also manually inspected. Thirty-three studies were included. The quality of the studies assessed in accordance with the Consolidated Health Economic Evaluation Reporting Standards checklist was good. All studies evaluated direct costs, apart from one which dealt only with indirect costs. Indirect costs were evaluated by 12 studies. The economic burden of HZ has increased over time. HZ management and drug prescriptions generate the highest direct costs. While increasing age, co-morbidities and drug treatment were found to predict higher direct costs, being employed was correlated with higher indirect costs, and thus with the onset age of the disease. Despite some differences among the selected studies, particularly with regard to indirect costs, all concur that HZ is a widespread disease which has a heavy social and economic burden.
Collapse
|
5
|
Levi M, Bellini I, Capecchi L, Pieri L, Bechini A, Boccalini S, Callaioli S, Gasparini R, Panatto D, Tiscione E, Bonanni P. The burden of disease of Herpes Zoster in Tuscany. Hum Vaccin Immunother 2014; 11:185-91. [PMID: 25483534 DOI: 10.4161/hv.35859] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Herpes zoster (HZ) is a disease caused by the reactivation of the latent α-herpes virus varicella zoster virus (VZV), for which, in Italy, a specific surveillance system does not exist, but around 200 000 cases are estimated each year. In older patients, who are at increased risk of developing HZ, symptoms are more severe and the chances to develop postherpetic neuralgia (PHN), the most severe complication, are substantially higher. A vaccine against HZ with demonstrated efficacy and an acceptable safety profile is now available and is recommended in Europe for adults >50 years. In anticipation of the possible introduction of an immunization programme for the elderly in Tuscany, the burden of disease caused by HZ and its complications was assessed through a retrospective analysis of the hospital discharge records between 2002 and 2012, using the ICD-9-CM 053 code. In the period 2002-2012, 4475 hospital admissions were registered with annual means of 368 hospitalizations and 39 day-hospital admissions. Most of the hospitalizations (68%) involved subjects > 65 years; the mean length of stay was 9.5 days. Slightly more than half (51.2%) of total hospital admissions were complicated cases. The most frequent were neurological complications (24.2% of total admissions), followed by ophthalmic complications (16.5%). Cases with neurological complications were those with the higher average length of stay and higher average costs for case. This study confirmed the epidemiological impact of HZ and its complications and the positive impact on morbidity that the introduction of the HZ vaccination could have in older age groups.
Collapse
Affiliation(s)
- Miriam Levi
- a Department of Health Sciences; University of Florence; Florence, Italy
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
6
|
Gabutti G, Franco E, Bonanni P, Conversano M, Ferro A, Lazzari M, Maggi S, Rossi A, Scotti S, Vitale F, Volpi A, Greco D. Reducing the burden of Herpes Zoster in Italy. Hum Vaccin Immunother 2014; 11:101-7. [PMID: 25483522 DOI: 10.4161/hv.34363] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/24/2022] Open
Abstract
Herpes Zoster (HZ) is a viral disease with painful neuro-dermatologic manifestations. Incidence increases with age. In Italy, the estimated incidence is 6.3 cases/1000 person/year; hospital admissions are less than 2%, 69% in patients aged over 65 years. The most frequent complication of HZ is Post-Herpetic Neuralgia (PHN) characterized by metameric pain, allodynia, and hyperalgesia. In Italy 20.6% and 9.2% of HZ patients experience PHN after 3 and 6 months, respectively. Available antiviral and analgesic treatments are relatively unsatisfactory in reducing pain and length of the disease. Prevention has recently become possible with the live attenuated vaccine Oka/Merck. Clinical studies show a reduction of 51% in the incidence of the disease, 61% of its burden and 67% of PHN in vaccinees. Protection seems to be long lasting and vaccine safety matches registration requirements. Available evidence suggests that the costs for QALY (less than € 20 000) and avoided cases is favorable. Due to the heavy burden of disease, it is time to offer this vaccination to elderly population.
Collapse
|
7
|
Pinchinat S, Cebrián-Cuenca AM, Bricout H, Johnson RW. Similar herpes zoster incidence across Europe: results from a systematic literature review. BMC Infect Dis 2013; 13:170. [PMID: 23574765 PMCID: PMC3637114 DOI: 10.1186/1471-2334-13-170] [Citation(s) in RCA: 155] [Impact Index Per Article: 14.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/29/2012] [Accepted: 03/06/2013] [Indexed: 11/25/2022] Open
Abstract
Background Herpes zoster (HZ) is caused by reactivation of the varicella-zoster virus (VZV) and mainly affects individuals aged ≥50 years. The forthcoming European launch of a vaccine against HZ (Zostavax®) prompts the need for a better understanding of the epidemiology of HZ in Europe. Therefore the aim of this systematic review was to summarize the available data on HZ incidence in Europe and to describe age-specific incidence. Methods The Medline database of the National Library of Medicine was used to conduct a comprehensive literature search of population-based studies of HZ incidence published between 1960 and 2010 carried out in the 27 member countries of the European Union, Iceland, Norway and Switzerland. The identified articles were reviewed and scored according to a reading grid including various quality criteria, and HZ incidence data were extracted and presented by country. Results The search identified 21 studies, and revealed a similar annual HZ incidence throughout Europe, varying by country from 2.0 to 4.6/1 000 person-years with no clearly observed geographic trend. Despite the fact that age groups differed from one study to another, age-specific HZ incidence rates seemed to hold steady during the review period, at around 1/1 000 children <10 years, around 2/1 000 adults aged <40 years, and around 1–4/1 000 adults aged 40–50 years. They then increased rapidly after age 50 years to around 7–8/1 000, up to 10/1 000 after 80 years of age. Our review confirms that in Europe HZ incidence increases with age, and quite drastically after 50 years of age. In all of the 21 studies included in the present review, incidence rates were higher among women than men, and this difference increased with age. This review also highlights the need to identify standardized surveillance methods to improve the comparability of data within European Union Member States and to monitor the impact of VZV immunization on the epidemiology of HZ. Conclusions Available data in Europe have shortcomings which make an accurate assessment of HZ incidence and change over time impossible. However, data are indicative that HZ incidence is comparable, and increases with age in the same proportion across Europe.
Collapse
Affiliation(s)
- Sybil Pinchinat
- Epidemiology Department, Sanofi Pasteur MSD, 8 rue Jonas Salk, Lyon, 69007, France
| | | | | | | |
Collapse
|
8
|
Şahin Ş, Çınar N, Okluoğlu T, Batum K, Karşıdağ S. Is Herpes Zoster Merely A Simple Neuralgia
Syndrome? ELECTRONIC JOURNAL OF GENERAL MEDICINE 2011. [DOI: 10.29333/ejgm/82741] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/21/2022]
|